CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory/relapsed acute B lymphocytic leukemia: Long-term follow-up results
Source : https://www.frontiersin.org/articles/10.3389/fonc.2022.1048296/full
BackgroundPatients with refractory/relapsed (r/r) acute B lymphocytic leukemia (B-ALL) can achieve complete response (CR) after chimeric antigen receptor T-cell (CAR-T) therapy, but recurrence occurs in the short term. To reduce...
Conclusions: Germline EP300 mutation and tumor somatic TP53 mutation are poor prognostic factors for posttransplant recurrence and survival in r/r B-ALL patients achieving CR after CAR-T therapy. The prognostic risk factors should be considered in adjusting treatment strategies to improve the efficacy of clinical diagnosis and treatment.
CAR T-cell Therapy for Relapsed/Refractory Diffuse Large B-c | OTT
Muscular dystrophies are a heterogeneous group of disorders characterized by clinical features of progressive muscle weakness and dystrophic features on pathological assessments of muscle biopsy specimens. The heterogeneity of muscular...
Conclusions: This case provides evidence for the use of CAR T-cell therapy in lymphoma patients with inherited degenerative disorders. Achieving remission of the lymphoma and subsequent administration of γ-globulin as well as zoledronic acid reduced the muscular dystrophy symptoms.
Efficacy and safety of blinatumomab in children with relapsed/refractory B cell acute lymphoblastic leukemia: A systematic review and meta-analysis
Source : https://www.frontiersin.org/articles/10.3389/fphar.2022.1032664/full
Objectives: Several clinical trials have been conducted to evaluate the effects of blinatumomab in childhood B cell acute lymphoblastic leukemia (B-ALL). We conducted this meta-analysis to validate the efficacy and...
Conclusions: Conclusion: According to this meta-analysis, blinatumomab shows potent therapeutic efficacy and limited AEs in children with R/R B- ALL.
A retrospective study on effectiveness of combined recombinant human interferon-α-1b, interleukin-2, and thalidomide for the treatment of acute myeloid leukemia in various disease states - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36660719/
For suitable patients, hematopoietic stem cell transplantation is still strong recommended. The ITI regimen may be an effective option for patients with AML who cannot tolerate conventional chemotherapy, including those...
Conclusions: For suitable patients, hematopoietic stem cell transplantation is still strong recommended. The ITI regimen may be an effective option for patients with AML who cannot tolerate conventional chemotherapy, including those with relapsed/refractory disease, those with a complete remission status but are MRD-positive, or those who...
MiR-128-3p as blood based liquid biopsy biomarker in childhood acute lymphoblastic leukemia
Source : https://www.sciencedirect.com/science/article/pii/S0890850823000026?via=ihub
Circulating microRNAs could serve as minimal-invasive MRD monitoring tools in ALL. * MiR-128-3p in platelet-free plasma predicts day 15 bone marrow flow cytometry MRD. * MiR-128-3p in exosome-enriched fractions correlated...
Conclusions: Our results show that circulating miRs are potential biomarkers of ALL MRD, asmiR-128-3p level both in PFP and EEF predicts day 15 FC MRD. In addition, the assessment of the EEF gave a more promising result.